Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20798392 | 1.00 | PIK3CD (0.39) | PIK3CDSLC6A7HCRTR2GRM1CHRM4 | |
| SCHEMBL17236136 | 0.84 | MAP4K4 (0.51) | PIK3CDSLC6A7HCRTR2GRM1 | |
| SCHEMBL17224999 | 0.84 | MAP4K4 (0.51) | PIK3CDSLC6A7HCRTR2GRM1 | |
| SCHEMBL17224998 | 0.84 | MAP4K4 (0.51) | PIK3CDSLC6A7HCRTR2GRM1 | |
| SCHEMBL23235680 | 0.80 | SMN1; SMN2 (0.54) | PIK3CDSLC6A7HCRTR2GRM1CHRM4 | |
| SCHEMBL17225022 | 0.79 | SMN1; SMN2 (0.34) | HCRTR2 | |
| SCHEMBL23235686 | 0.77 | GRM1 (0.47) | SLC6A7GRM1 | |
| SCHEMBL29241190 | 0.77 | GRM1 (0.47) | SLC6A7GRM1 | |
| SCHEMBL22156989 | 0.76 | KCNH2 (0.49) | PIK3CDHCRTR2CHRM4ROCK2PRKG1 | |
| SCHEMBL27176714 | 0.76 | KCNH2 (0.49) | PIK3CDHCRTR2CHRM4ROCK2PRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3679030-B1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | ZYDUS LIFESCIENCES LTD (IN) | 2024-03-27 | — | — | EP | disclosed |
| EP-3679030-A1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | Cadila Healthcare Limited (IN) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207738-A1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | ZYDUS LIFESCIENCES LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| WO-2019049021-A1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207738-A1 | A PROCESS FOR PREPARATION OF TRIAMINOPYRIMIDINE COMPOUND AND INTERMEDIATES THEREOF | DPYD, SAMHD1, NUDT1 | PIK3CD 1263/4885SLC6A7 1593/4885HCRTR2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.